GFPC > Publications GFPC

Publications GFPC

Nondisruptive p53 Mutations-ClinCancerRes-Molina

Nondisruptive p53 Mutations Are Associated with Shorter
Survival in Patients with Advanced Non–Small Cell Lung
Cancer

Molina-Vila MA1, Bertran-Alamillo J2, Gascó A3, Mayo-de-las-Casas C2, Sánchez-Ronco M4, Pujantell-Pastor L3, Bonanno L5, Favaretto AG5, Cardona AF6,Vergnenègre A7, Majem M8, Massuti B9, Morán T10, Carcereny E10, Viteri S3, Rosell R11.

Clin Cancer Res. 2014 Sep 1;20(17):4647-59. doi: 10.1158/1078-0432.CCR-13-2391. Epub 2014 Apr 2.

Ann Oncol-2014-Moran-2147-55 Two biomarker-directed randomized trials – BREC

Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies

Moran T, Wei J, Cobo M, Qian X, Domine M, Zou Z, Bover I, Wang L, Provencio M, Yu L, Chaib I, You C, Massuti B, Song Y, Vergnenegre A, Lu H, Lopez-Vivanco G, Hu W, Robinet G, Yan J, Insa A, Xu X, Majem M, Chen X, de Las Peñas R, Karachaliou N, Sala MA, Wu Q, Isla D, Zhou Y, Baize N, Zhang F,Garde J, Germonpre P, Rauh S, ALHusaini H, Sanchez-Ronco M, Drozdowskyj A, Sanchez JJ, Camps C, Liu B, Rosell R; Spanish Lung Cancer Group;French Lung Cancer Group; Comprehensive Cancer Centre of Drum Tower Hospital in Nanjing.

Ann Oncol. 2014 Nov;25(11):2147-55. doi: 10.1093/annonc/mdu389. Epub 2014 Aug 27

Essai GFPC-IFCT 02-01 EJC 2016

Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation: a randomised phase II trial GFPC – IFCT 02-01

Pierre Fournela, , , Alain Vergnenégreb, Gilles Robinetc, Hervé Lénad, Radj Gervaise, Hervé Le Caerf, Pierre-Jean Souquetg, Jean-Michel Chavaillonh, Marie-Cécile Bozonnati, Jean-Pierre Daurèsi, Christos Chouaidj, Isabelle Martel-Lafayk, for GFPC and IFCT teaml1

Journal of Cancer 52 (2016) 181e187

POSTERS ET ABSTRACT GFPC ESMO 2014

 ESOGIA
SUJETS JEUNES
EGFR RETRO

An open multicenter phase II trial of docetaxel-gemcitabine in Charlson-score and performans status (PS) selected elderly patients with stage IIIB pleural/IV non-small-cell lung cancer (NSCLC) : the GFPC 02-02a study

Critical Reviews in Oncology/Hematology 2007;64:73-81

[pdf]Le Caer et al. Crit Rev Oncol-Hematol 2007_73-81[/pdf]

Lung Cancer 2013

Assessment of palliative care for advanced non-small-cell lung cancer in France: A prospective observational multicenter study (GFPC 0804 study)

Transl Lung Cancer Res 2013;2(3):200-207

Elderly patients are often excluded from clinical trials, yet more than two-thirds of patients
diagnosed with lung cancer are over 65 years old. It is therefore important to develop specific tools and trials for this specific patient population.

Annals of Oncology 2013 Feb 13

Multicentre phase II study of cisplatin-etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study

Clin Lung Cancer 2013;14(2)103-107

Cost Analysis of Erlotinib Versus Chemotherapy for First-Line Treatment of Non–small-Cell Lung Cancer in Frail Elderly Patients Participating in a Prospective Phase 2 Study (GFPC 0505)

Cancer 2012;12(1):301

Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504)